Survival for pregnant women diagnosed with malignant melanomaduringpregnancyhasrepresentedacontroversyat least since the 1950s. The disease was previously considered hormone related and therefore thought to be influenced by the high estrogen levels during pregnancy. Several uncontrolled case-series have demonstrated poorer survival for women with pregnancy-associated melanomas [5] [6] . More recentlypublishedcontrolledstudiesshowthatinitialtumor thickness seems to be the only important prognostic factor, possibly besides tumor site. Three retrospective populationbasedstudieshavefailedtodemonstratethatsurvivalisdifferentforpregnantwomencomparedtonon-pregnantcontrols [3, 7, 8] .Severalcase-controlstudiesandcaseserieshavebeen published since the mid-1980s, and 6 well-controlled studies all conclude that similar survival is observed for pregnant womenwithmalignantmelanomastageIorIIandnon-pregnantwomenwithsimilardiseasecharacteristics [9] [10] [11] [12] [13] [14] .Somewhat shorter disease-free intervals in pregnant women were foundbyReintgenandSlinguff,whoalsohadoverlappingpatientpopulations [9, 12] .Asoftoday,thereisnorealevidence suggestingthatpregnancy-inducedhormonal changeshavean adverseeffectonsurvivalinwomendiagnosedwithmelanomaduringpregnancy.Neithertheuseoforalcontraceptives norhormonereplacementtherapyhasbeenfoundtoworsen theprognosis [15, 16] .
For women with subsequent pregnancies after malignant melanoma, the overall prognosis is good [3, 7] . This might, however,beaselectedgroupofwomenwithinitiallylowstage tumors,whohaveoptedtobecomepregnantbecausetheyfeel wellandhealthyagainaftertheirdisease.Thisisdescribedas the 'healthy mother effect' [17] . Although higher birth rates maybeconnectedwithalowerriskformalignantmelanoma, it does not necessarily reflect a protective effect of the pregnancy,butmaybeaconsequenceoftheself-selectionprocess.
Guidelines or recommendations for counseling women whowanttogetpregnantafterhavingamalignantdiseaseare largelylacking.Ontheotherhand,case-to-casebasedcounMalignantmelanomaisamajorcauseofcancerdeathamong womenofchildbearingage.Itisoneofthemostcommoncancertypesdiagnosedduringpregnancy,besidesbreastcancer andcervicalcancer.Thecoincidenceofcancerandpregnancy isincreasing,aswomentodaypostponechildbearingandcancer incidence is rising. Of 1000 pregnancies, 0.1-2.8 are reportedcomplicatedwithmalignantmelanoma [1] ,althoughit appearstovarygeographicallyand/orwithskintype.Worth noticingisthatmoststudiesconcernincidenceofmelanomas diagnosedduringpregnancy,butsomeevenincludecases12 monthspost-partum.
Asreferredinthearticle'Advancedmetastaticmelanoma inpregnancy:amultidisciplinarychallenge'publishedinthis numberofOnkOlOgie [2] ,8%ofallcancersduringpregnancy aremalignantmelanomas.In2Nordicpopulation-basedstudies, much higher incidences were found, 31% in the NorwegianandasimilarnumberintheSwedishstudy,whichmight reflectthegeneralhighincidenceofmalignantmelanomain themorefair-skinnedpopulationofScandinavia [3, 4] .
In the case report in this issue, the patient was already diagnosed 2.5 years before her pregnancy with a malignant melanoma stage II and Clark level IV, and she was receiving systemic therapy because of metastatic disease when she became pregnant. During her pregnancy, also liver and bonemetastasesweredetected.Asmallbuthealthybabywas delivered before gestational week 29 by a planned Caesarian section. The patient, however, died within 3 months. A multidisciplinary team followed the patient and her unborn child by weekly conferences, to optimize the treatment and management for both. It is not mentioned whether she did undergo a sentinel lymph node biopsy at diagnosis, and it remains unclear whether she was advised against becoming pregnantwhileshewasreceivinginterferonalpha.Themultidisciplinarymanagementisunderscoredandappearstoreflectgoodmedicalcarebothforthemotherandthefetus,attendingtothechallengingsituationatanindividualorfamily basis,likerecommended. Stensheim selingseemstobefruitful,beingabletotakepersonalcharacteristicsintoaccountsuchasthewomen'sage,stageofdisease and tumor thickness, and desire to become pregnant. Most authorsrecommenda2-3yearspostponementofapregnancy after a malignant diagnosis, to avoid relapses during pregnancyorshortlyafter,orworse,amotherlesschild.Itisstill, however,importanttokeepinmindthattheprognosisforthis diseaseisunpredictable. Fetalrisksofmaternalcancertreatmentarewelldescribedin thepaperbyGottschalketal.withamini-reviewoftheliterature [2] .Ingeneral,treatmentinthesecondandthirdtrimester might not harm the fetus, but both diagnostic procedures and treatmentshouldbethoroughlyevaluatedbasedongestational week,themother'shealth,cancertypeandstage,andgeneral diagnosticandtreatmentguidelines.Additionally,CTandPET (F-FDGmightcrosstheplacentaandexposethefetustohigh radiation doses) should be avoided, and radiotherapy before gestationalweek25mayresultinfetalmentalretardation [18] . A case-report like the one in this issue does not provide knowledgeofcancerpatients'outcomeingeneral.Itis,however, of great value to share the story to gain more knowledge about outcomes for fetuses that are exposed to cancer therapy.Allcancertherapyprovidedtopatientsduringpregnancy should be described thoroughly as studies can hardly besetupforsuchsituations.Ideally,aninternational'Cancer during Pregnancy Register' could be set up, but ethical and other restrictions are likely to interfere with such a suggestion.Collectionsofcaseseries,however,inthefuturewillbe ofgreatvalueandinterestforclinicians,theaffectedpatients, andtheirfamilies.
